[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 5 of about 5
1. Cobellis L, Messalli EM, Calabrese E, Pecori E, Gioino E, Cobellis G: [Vena cava filter in patients with gynecologic cancer complicated by pulmonary embolism and progressive hypercoagulability]. Minerva Ginecol; 2002 Feb;54(1):63-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vena cava filter in patients with gynecologic cancer complicated by pulmonary embolism and progressive hypercoagulability].
  • The aim of the study was to verify the validity of placement of a vena cava filter in patients with gynecologic cancer complicated by pulmonary embolism and progressive persistent hypercoagulability.
  • In this study, a gynecologic tumor was diagnosed, one presented endometrial carcinoma and the other ovarian papillary carcinoma, after the position of vena cava filter and treatment with urokinasi (2.800.000 UI/ml) it was possible to do surgery followed by radiation therapy in the first case and chemotherapy in the second.
  • This has enabled surgery and anticoagulation therapy and has prevented the movement of any other emboli, which were later dissolved by fibrinolytic agents, and the effectiveness result was the arrest of progressive hypercoagulability moved by tumor cell.
  • The serious conditions that were related to prior embolism and to a persistent thrombotic state characterized by progressive hypercoagulability did not make it possible to perform surgery or any other type of therapy because of absolute contraindications.
  • The decision to place the filter could thus become the first step towards subsequent improvements, that are also tied to the possibility of performing surgery for removing tumor, arrest of progressive hypercoagulability due to tumor cell, allow chemotherapy or radiation treatment.
  • [MeSH-major] Carcinoma, Adenosquamous / complications. Carcinoma, Papillary / complications. Endometrial Neoplasms / complications. Ovarian Neoplasms / complications. Pulmonary Embolism / therapy. Thrombophilia / therapy. Vena Cava Filters

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11828272.001).
  • [ISSN] 0026-4784
  • [Journal-full-title] Minerva ginecologica
  • [ISO-abbreviation] Minerva Ginecol
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


2. Martínez-Monge R, Nagore G, Cambeiro M, Garrán C, Villafranca E, Jurado M: Intravaginal 1-week high-dose-rate brachytherapy alone for Stages I-II endometrial cancer. Brachytherapy; 2007 Jul-Sep;6(3):195-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravaginal 1-week high-dose-rate brachytherapy alone for Stages I-II endometrial cancer.
  • METHODS AND MATERIALS: From December 1999 to February 2005, 50 patients with International federation of gynecology and obstetrics Stages IA-IIB endometrioid endometrial adenocarcinoma were treated with total abdominal hysterectomy and bilateral salpingo-oophorectomy followed by postoperative HDR brachytherapy alone.
  • CONCLUSIONS: The results reported in this study are in agreement with previous reports of postoperative HDR brachytherapy alone in early-stage endometrial cancer.
  • [MeSH-major] Adenocarcinoma, Clear Cell / radiotherapy. Brachytherapy / methods. Carcinoma, Adenosquamous / radiotherapy. Endometrial Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Feasibility Studies. Female. Follow-Up Studies. Humans. Hysterectomy. Middle Aged. Neoplasm Staging / methods. Ovariectomy / methods. Postoperative Care / methods. Radiotherapy, Adjuvant / methods. Retrospective Studies. Treatment Outcome. Vagina

  • Genetic Alliance. consumer health - Endometrial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681240.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Lambrou NC, Gómez-Marín O, Mirhashemi R, Beach H, Salom E, Almeida-Parra Z, Peñalver M: Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival. Gynecol Oncol; 2004 Jun;93(3):653-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival.
  • OBJECTIVE: To evaluate the survival impact of residual disease at the time of primary surgery for patients with Stage III and IV endometrial carcinoma; to assess morbidity associated with surgical cytoreduction.
  • METHOD: All patients with endometrial carcinoma who underwent primary surgical therapy at the University of Miami between January 1, 1990 and June 1, 2002 were identified.
  • Patients meeting FIGO criteria for Stage III or IV disease were selected.
  • Papillary serous and clear cell histology was excluded.
  • RESULTS: Eighty-five patients were identified: 66 Stage III and 19 Stage IV.
  • Only Stage IIIC and Stage IV were included in survival analysis: 72% (33 Stage IIIC, 9 Stage IV) had optimal cytoreduction and 28% (6 Stage IIIC, 10 Stage IV) had suboptimal cytoreduction.
  • The median survival for Stage IIIC and IV disease was 6.7 months for patients with suboptimal cytoreduction and 17.8 months for patients with optimal cytoreduction (P = 0.001).
  • CONCLUSIONS: Overall survival is lower and morbidity is higher in patients with advanced endometrial carcinoma having suboptimal cytoreduction at the time of primary surgery.
  • Patients with suspected advanced stage endometrial carcinoma should be counseled on the potential benefits of optimal cytoreductive surgery.
  • [MeSH-major] Endometrial Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Adenosquamous / surgery. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / pathology. Carcinoma, Endometrioid / radiotherapy. Carcinoma, Endometrioid / surgery. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Morbidity. Neoplasm Staging. Radiotherapy, Adjuvant. Survival Rate

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15196860.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Li FQ, Liu Q, Han YL, Wu B, Yin HL: Sperm protein 17 is highly expressed in endometrial and cervical cancers. BMC Cancer; 2010;10:429
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sperm protein 17 is highly expressed in endometrial and cervical cancers.
  • It has been proposed as a useful target for tumor-vaccine strategies and a novel marker to define tumor subsets and predict drug response.
  • This study aimed to investigate the expression of Sp17 in endometrial and cervical cancer specimens, its possible correlation with the pathological characteristics, and its value in the diagnosis and immunotherapy of the related cancers.
  • METHODS: The monoclonal antibodies against human Sp17 were produced as reagents for the analysis and immunohistochemistry was used to study two major kinds of paraffin-embedded gynecological cancer specimens, including 50 cases of endometrial cancer (44 adenous and 6 adenosquamous) and 31 cases of cervical cancer (15 adenous and 16 squamous).
  • Normal peripheral endometrial and cervical tissues were used as controls.
  • RESULTS: Sp17 was found in 66% (33/50) of the patients with endometrial cancer and 61% (19/31) of those with cervical cancer.
  • Its expression was found in a heterogeneous pattern in the cancer tissues.
  • The expression was not correlated with the histological subtype and grade of malignancy, but the staining patterns were different in endometrial and cervical cancers.
  • The hyperplastic glands were positive for Sp17 in the normal peripheral endometrial and cervical tissues in 10% (8/81) of the patients.
  • CONCLUSIONS: Sp17 is highly expressed in human endometrial and cervical cancers in a heterogeneous pattern.
  • Although the expression frequency of Sp17 is not correlated with the histological subtype, the staining pattern may help to define endometrial and cervical cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, Surface / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / metabolism. Carrier Proteins / metabolism. Endometrial Neoplasms / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. Case-Control Studies. Female. Humans. Immunization. Immunoenzyme Techniques. Immunoglobulin G / immunology. Mice. Mice, Inbred BALB C. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Tissue Array Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2007 Apr 15;120(8):1739-47 [17230514.001]
  • [Cites] Lancet. 2003 Jun 28;361(9376):2217-25 [12842378.001]
  • [Cites] J Immunother. 2008 Oct;31(8):693-703 [18779750.001]
  • [Cites] J Transl Med. 2009;7:61 [19604394.001]
  • [Cites] BMC Cancer. 2009;9:323 [19744347.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1508-10 [11222401.001]
  • [Cites] Blood. 2003 Sep 15;102(6):2308-9 [12959941.001]
  • [Cites] Int J Cancer. 2004 Mar 1;108(6):805-11 [14712480.001]
  • [Cites] J Histochem Cytochem. 2004 Apr;52(4):549-54 [15034007.001]
  • [Cites] Br J Dermatol. 2004 Apr;150(4):780-2 [15099386.001]
  • [Cites] Eur J Haematol. 2004 Oct;73(4):280-4 [15347315.001]
  • [Cites] Dev Biol. 1994 Oct;165(2):688-701 [7525387.001]
  • [Cites] Biol Reprod. 1995 Sep;53(3):579-90 [7578682.001]
  • [Cites] Biochim Biophys Acta. 1996 Jul 17;1307(3):263-6 [8688458.001]
  • [Cites] Int Rev Cytol. 1998;177:57-113 [9378618.001]
  • [Cites] Biol Reprod. 1998 Mar;58(3):794-800 [9510968.001]
  • [Cites] J Cell Biochem Suppl. 1997;28-29:90-100 [9589353.001]
  • [Cites] Am J Hematol. 2005 Sep;80(1):6-11 [16138340.001]
  • [Cites] Hum Pathol. 2005 Dec;36(12):1289-93 [16311122.001]
  • [Cites] BMC Cancer. 2006;6:23 [16438728.001]
  • [Cites] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2006 Sep;22(5):638-40 [16948914.001]
  • [Cites] Biochem J. 2001 Jul 1;357(Pt 1):25-31 [11415432.001]
  • [Cites] Eur J Immunol. 2001 Aug;31(8):2277-83 [11477539.001]
  • [Cites] Blood. 2001 Oct 1;98(7):2160-5 [11568003.001]
  • [Cites] J Reprod Med. 2002 Mar;47(3):173-89; discussion 189-90 [11933681.001]
  • [Cites] Cancer. 2002 May 1;94(9):2447-53 [12015770.001]
  • [Cites] Blood. 2002 Aug 1;100(3):961-5 [12130509.001]
  • [Cites] Cancer Lett. 2002 Dec 5;186(2):201-9 [12213290.001]
  • [Cites] Scand J Immunol. 2002 Oct;56(4):429-33 [12234264.001]
  • [Cites] Reproduction. 2002 Dec;124(6):767-74 [12530914.001]
  • [Cites] Dev Immunol. 2002 Jun;9(2):97-102 [12739786.001]
  • [Cites] Int J Gynecol Cancer. 2007 Mar-Apr;17(2):426-32 [17309563.001]
  • (PMID = 20712874.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Immunoglobulin G; 0 / SPA17 protein, human
  • [Other-IDs] NLM/ PMC2931487
  •  go-up   go-down


5. Hall DJ, Martin DA, Kincaid K: Filgrastim support during combination chemotherapy using cisplatin, doxorubicin, and cyclophosphamide to treat advanced or recurrent endometrial cancer: a clinical study and literature review. Eur J Gynaecol Oncol; 2003;24(6):481-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Filgrastim support during combination chemotherapy using cisplatin, doxorubicin, and cyclophosphamide to treat advanced or recurrent endometrial cancer: a clinical study and literature review.
  • In a private practice setting, 16 patients with advanced or recurrent endometrial carcinoma received cisplatinum 50 mg/m2, doxorubicin 50 mg/m2, and cyclophosphamide 750 mg/m2 every three weeks.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Endometrial Neoplasms / drug therapy. Granulocyte Colony-Stimulating Factor / administration & dosage. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / pathology. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / pathology. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cystadenocarcinoma, Papillary / drug therapy. Cystadenocarcinoma, Papillary / mortality. Cystadenocarcinoma, Papillary / pathology. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Filgrastim. Humans. Neoplasm Metastasis. Neutropenia / prevention & control. Recombinant Proteins. Treatment Outcome

  • Genetic Alliance. consumer health - Endometrial cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14658586.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; PVI5M0M1GW / Filgrastim; Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement